---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248695129.md"
description: "ZHEJIANG ZHENYUAN stated on the interactive platform that the innovative new drug for cancer pain treatment is still in the exploratory research stage and there are no plans for market launch at this time"
datetime: "2025-07-16T01:10:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248695129.md)
  - [en](https://longbridge.com/en/news/248695129.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248695129.md)
generator: "portal-rs"
---

# 

ZHEJIANG ZHENYUAN stated on the interactive platform that the innovative new drug for cancer pain treatment is still in the exploratory research stage and there are no plans for market launch at this time

### Related Stocks

- [000705.CN](https://longbridge.com/en/quote/000705.CN.md)

## Related News & Research

- [Here’s what Elon Musk’s trillion dollars can buy](https://longbridge.com/en/news/296179589.md)
- [Evolve Future Leadership Fund - ETF Hedged declares CAD 0.21 dividend](https://longbridge.com/en/news/296299467.md)
- [BioSyent GAAP EPS of C$0.25, revenue of C$19.87M](https://longbridge.com/en/news/296538491.md)
- [Meta Wolf’s Lubanco Pte. Ltd., closely associated with Supervisory Board member Thomas Wolf, buys shares for EUR 1,402.5](https://longbridge.com/en/news/296554860.md)
- [People Inc CEO Neil Vogel files initial beneficial ownership statement](https://longbridge.com/en/news/296143489.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**